Scientists at Foundation for Biomedical Research (SFBR) in Texas claimed to have developed the BoNT-detecting substances or the antibodies – proteins made by the body to fight diseases – found in llamas. The llama antibodies, called single domain antibodies (sdAb) are molecularly flexible, unlike conventional antibodies, ScienceDaily reported. BoNTs directly hit the nervous system, resulting in paralysis that can be so severe as to require life support on a mechanical ventilator for weeks to months.

For the full story, Click Here

The North American Metal Packaging Alliance, Inc. (NAMPA) supports the U.S. Food and Drug Administration’s (FDA) announcement today to continue its ongoing scientific research and evaluation of bisphenol A (BPA). At the same time, FDA officials reiterated that consumers can continue to use safely existing products that contain BPA. The FDA announcement clearly noted that BPA exposure is not proven to harm children or adults which is consistent with other international regulatory bodies.

For the full story, Click Here

Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. ACTEMRA is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat RA, and may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs.

For the full story, Click Here

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company announced. The efficacy and safety of Cymbalta for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who initially had responded to treatment with Cymbalta 60-120 mg/day during a 26-week open-label phase were randomly assigned to receive Cymbalta 60-120mg/day or placebo.

For the full story, Click Here